Association of helicobacter pylori dupA with the failure of primary eradication

Journal of Clinical Gastroenterology

Volumn 46, Issue 4, 2012, Pages 297-301

  Shiota, Seiji ^a   Nguyen, Lam Tung ^a   Murakami, Kazunari ^a   Kuroda, Akiko ^a   Mizukami, Kazuhiro ^a   Okimoto, Tadayoshi ^a   Kodama, Masaaki ^a   Fujioka, Toshio ^a   Yamaoka, Yoshio ^a,b  

^a OITA UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

dupA; eradication rate; Helicobacter pylori

Indexed keywords

CLARITHROMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE CLASSIFICATION; DRUG TREATMENT FAILURE; DUPA GENE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

ADULT; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84858866702     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318243201c     Document Type: Article

References (26)

1. Asaka M, Kato M, Takahashi S, et al. Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition. Helicobacter. 2010;15:1-20.
2. Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009;14:86-90.
3. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2J Clin Microbiol. 2007;45:4006-4010. (Pubitemid 350274884)
4. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010;7:629-641.
5. Russo F, Berloco P, Cuomo R, et al. Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther. 2003;17:421-428. (Pubitemid 36259405)
6. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz). 2009;57:45-56.
7. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;24:273-280. (Pubitemid 43972895)
8. Zhao J, Wang J, Yang L, et al. Influence of Helicobacter pylori genotype on triple eradication therapy. J Gastroenterol Hepatol. 2007;22:2251-2255. (Pubitemid 350145625)
9. Lu H, Hsu P, Graham D, et al. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology. 2005;128:833-848. (Pubitemid 40523536)
10. Shiota S, Matsunari O, Watada M, et al. Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog. 2010;2:13.
11. Nguyen L, Uchida T, Tsukamoto Y, et al. Helicobacter pylori dupA gene is not associated with clinical outcomes in the Japanese population. Clin Microbiol Infect. 2010;16:1264-1269.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing M100-S18 18th Informational Supplement. Clinical and Laboratory Standards Institute, Waynee: PA; 2008.
13. Yamaoka Y, Kodama T, Kita M, et al. Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter. 1998;3:241-253. (Pubitemid 128656776)
14. Elviss N, Owen R, Xerry J, et al. Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother. 2004;54:435-440. (Pubitemid 39177466)
15. Agudo S, Pérez-Pérez G, Alarcón T, et al. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48:3703-3707.
16. De Francesco V, Margiotta M, Zullo A, et al. Claritromycin resistance and Helicobacter pylori genotypes in Italy. J Microbiol. 2006;44:660-664. (Pubitemid 46409796)
17. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther. 2004;19:407-414. (Pubitemid 38297109)
18. van der Hulst R, van der Ende A, Dekker F, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113:25-30. (Pubitemid 27281754)
19. Maeda S, Yoshida H, Ikenoue T, et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut. 1999;44:336-341. (Pubitemid 29119327)
20. Grayson M, Eliopoulos G, Ferraro M, et al. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989;8:888-889. (Pubitemid 19265874)
21. Hunt R. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993;88:481-483. (Pubitemid 23106576)
22. Peterson W. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11 (Suppl 1):21-25.
23. Schubert M, Peura D. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860. (Pubitemid 351783299)
24. Imagawa S, Ito M, Yoshihara M, et al. Helicobacter pylori dupA and gastric acid secretion are negatively associated with gastric cancer development. J Med Microbiol. 2010;59(Pt 12):1484-1489.
25. Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007;8:2701-2717. (Pubitemid 350193712)
26. Huang JQ, Zheng GF, Hunt RH, et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol. 2005;11: 2726-2732. (Pubitemid 40704237)